NCT05524857View on ClinicalTrials.gov

Combination of Fedratinib and Decitabine for Myeloproliferative Neoplasms (MPN)- Accelerated Phase (AP)/Blast Phase (BP)

PHASE1TerminatedINTERVENTIONAL
Enrollment

2

Participants

Timeline

Start Date

January 28, 2022

Primary Completion Date

April 9, 2024

Study Completion Date

April 9, 2024

Conditions
Myeloproliferative Neoplasm
Interventions
DRUG

Fedratinib Oral Capsule 300 mg

300 mg by mouth, once daily

DRUG

Decitabine 20 mg/m2

20 mg/m2 for injection, for intravenous use

DRUG

Fedratinib Oral Capsule 400 mg

400 mg by mouth, once daily

Trial Locations (1)

10032

New York Presbyterian Hospital/Columbia University Irving Medical Center, New York

Sponsors

Collaborators (1)

Bristol-Myers Squibb
All Listed Sponsors
collaborator

Bristol-Myers Squibb

INDUSTRY

lead

Joseph Jurcic

OTHER

NCT05524857 - Combination of Fedratinib and Decitabine for Myeloproliferative Neoplasms (MPN)- Accelerated Phase (AP)/Blast Phase (BP) | Biotech Hunter | Biotech Hunter